Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 38 of 55
Archive
Week ahead includes updates from drugs giant AstraZeneca, mobile phones operator Vodafone Group, British Gas-owner Centrica, and postal delivery firm Royal Mail Group
Its drug targeting people with chronic obstructive pulmonary disease failed to make a statistically meaningful difference
The FTSE 100 drugmaker has been selling off non-core assets in recent years as it narrows its focus on three primary areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory
The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers in London on Tuesday
Steve Harris, Circassia’s chief executive, said he expected to see strong revenue growth in 2018
AZ’s Imfinzi was paired with tremelimumab, an immune checkpoint blocker, to treat patients with non-small cell lung cancer
Chairman Iain Ross will step back into a non-executive role following the appointment
Stocks consolidated gains at the death with bid stock Shire the best performing blue-chip
Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation
The broker is still enamoured of the UK big hitters but doesn't expect it to be plain sailing for either
Isreali drugmaker will get a US$10mln upfront payment from MedImmune in the deal
The US FDA has accepted AstraZeneca’s biologics licence application for Moxetumomab Pasudotox while the European Medicines Agency will review the company's marketing authorisation application for Lynparza
The US broker also raised its target price for the FTSE 100-listed firm to 5,600p, up from 5,075p previously, with the shares trading at 4,865p in mid-morning trading
Investments and investor services
FTSE 100 closed down 121 points at 7,042, joining other European benchmarks, which saw red
Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
Investments and investor services
A look at some of today's top risers and fallers in London
Investments and investor services
The UK's blue-chip index closes up 20.84 points to 7,234.81
Investments and investor services
RELX is expected to see revenue and profit growth, whereas ConvaTec will report on what's seen as a disappointing year.
